Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds
- 9 May 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Organometallics
- Vol. 27 (11) , 2405-2407
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cancer Control Opportunities in Low- and Middle-income CountriesCA: A Cancer Journal for Clinicians, 2007
- Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancerAnti-Cancer Drugs, 2006
- From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)Journal of Inorganic Biochemistry, 2006
- Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical MethodologyChemical Reviews, 2006
- Platinum Complexes as Anticancer AgentsRecent Patents on Anti-Cancer Drug Discovery, 2006
- Metal complexes in medicinal chemistry: new vistas and challenges in drug designDalton Transactions, 2005
- Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteinsJournal of Analytical Atomic Spectrometry, 2005
- Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinomaEuropean Journal of Cancer, 2004
- Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopyJournal of Analytical Atomic Spectrometry, 2003
- Non-Platinum Chemotherapeutic MetallopharmaceuticalsChemical Reviews, 1999